# ABEMA Alone or in COMBO With MK-6482

> **NCT04627064** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 11 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** MK-6482

## Key facts

- **NCT ID:** NCT04627064
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-31
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-08-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627064, "ABEMA Alone or in COMBO With MK-6482". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04627064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*